Retatrutide: The Next-Generation GLP-1 — What Delray Beach Patients Should Know

Why Everyone Is Suddenly Asking About Retatrutide

Retatrutide is the first weight loss medication to target three metabolic receptors at once — GLP-1, GIP, and glucagon — and in mid-stage clinical trials it produced an average weight loss of about 24% of body weight over 48 weeks. That is the largest reduction ever recorded for an anti-obesity medication in a clinical trial, outpacing both semaglutide and tirzepatide.

Patients across Delray Beach and South Florida are already searching for "retatrutide near me" and "reta peptide" — often before knowing what the medication actually is, whether it's approved, or how it compares to the GLP-1 programs available today. This guide covers what retatrutide is, what the research actually shows, its current FDA status, and what Delray Beach patients can do right now while the medication moves through final trials.

At AmpUp Wellness, medical weight loss is supervised by David Patterson, APRN, a board-certified nurse practitioner with over 20 years of clinical experience — so this overview reflects how a clinician actually evaluates new metabolic medications, not hype.

What Is Retatrutide?

Retatrutide is an investigational injectable medication developed by Eli Lilly, the same company behind tirzepatide (Mounjaro/Zepbound). It belongs to the incretin-based family of metabolic medications, but it goes a step further than anything currently on the market.

Where semaglutide activates one receptor (GLP-1), and tirzepatide activates two (GLP-1 and GIP), retatrutide is a triple agonist — it also activates the glucagon receptor. That third mechanism appears to increase energy expenditure, meaning the body burns more calories at rest, in addition to the appetite regulation and improved insulin response the other two receptors provide.

In practical terms, the three mechanisms work together like this:

• GLP-1 activation reduces appetite, slows stomach emptying, and improves blood sugar control
• GIP activation enhances insulin sensitivity and may reduce nausea compared to GLP-1 alone
• Glucagon activation increases energy expenditure and supports fat metabolism in the liver

Retatrutide vs Semaglutide vs Tirzepatide: What the Numbers Show

Head-to-head comparison trials have not been completed, but the published trial data gives a reasonable picture of relative effectiveness:

• Semaglutide (Wegovy): roughly 15% average body weight loss over 68 weeks in the STEP 1 trial
• Tirzepatide (Zepbound): roughly 20% average body weight loss over 72 weeks at the highest dose in SURMOUNT-1
• Retatrutide: roughly 24% average body weight loss over just 48 weeks at the highest dose in its Phase 2 trial — and notably, weight loss had not yet plateaued when the trial ended

Two details from the retatrutide Phase 2 data stand out clinically. First, every single participant on the higher doses lost at least 5% of body weight — a response rate no other medication has matched. Second, participants with fatty liver disease saw dramatic reductions in liver fat. These are meaningful signals, though Phase 3 trials must confirm them in larger populations.

It's also worth being honest about the trade-offs: gastrointestinal side effects (nausea, constipation) were common, as with all incretin medications, and the glucagon mechanism can raise heart rate modestly — something Phase 3 safety data will clarify.

Is Retatrutide FDA-Approved? Can I Get It in Delray Beach?

No — retatrutide is not yet FDA-approved. It is currently in Phase 3 clinical trials (the TRIUMPH program), with results expected to roll out through 2026. Until approval, there is no legitimate pharmaceutical-grade retatrutide available by prescription anywhere in the United States, including Delray Beach.

That matters because demand has created a gray market. Websites selling "reta peptide" as a research chemical are not selling a regulated pharmaceutical product — purity, dosing accuracy, and sterility are unverified, and using unapproved research compounds for weight loss is unsafe. A board-certified provider cannot recommend that path, and we'd urge you to be skeptical of any clinic or website that claims to offer retatrutide today.

The good news: the currently available GLP-1 medications are highly effective when properly supervised. Most patients in our medical weight loss program in Delray Beach lose 15–20% of their body weight with semaglutide or tirzepatide protocols, monthly follow-ups, and body-composition tracking.

What Delray Beach Patients Can Do Right Now

If retatrutide's trial results caught your attention, the practical takeaway isn't to wait on the sidelines until 2026 — it's that incretin-based medicine works, and the current generation is already delivering results that would have seemed impossible five years ago.

At AmpUp Wellness in Delray Beach, David Patterson, APRN builds each weight loss plan around your labs, health history, and goals. For eligible patients, that may include a clinician-supervised semaglutide or GLP-1 protocol, paired with nutrition guidance and monthly in-person accountability.

Progress is tracked with InBody body composition testing rather than the scale alone — so you can see fat mass falling while muscle is preserved, which is the difference between losing weight and actually improving your metabolic health. When retatrutide (or any next-generation option) earns FDA approval, patients already established in a supervised program will be first in line to discuss whether switching makes sense.

Who Is a Candidate for GLP-1 Therapy Right Now?

While retatrutide finishes its trials, the candidacy criteria for today's incretin medications are well established. In general, adults may qualify for a supervised GLP-1 protocol if they have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as prediabetes, high blood pressure, high cholesterol, or sleep apnea.

Just as important is who should not use these medications: patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, or who are pregnant or planning pregnancy. This screening is exactly why "medical" belongs in medical weight loss — a proper intake at our Delray Beach clinic reviews your history, medications, and labs before any prescription is written.

Candidacy also isn't purely about numbers. The patients who succeed long-term are the ones ready to pair medication with protein-forward nutrition, strength training to protect muscle mass, and monthly accountability. Medication opens the metabolic window; habits determine what you build through it.

Why Muscle Preservation Matters More With Stronger Medications

Here's a nuance the headlines about retatrutide's 24% weight loss miss: the faster and larger the weight loss, the greater the risk that a meaningful share of it comes from lean muscle rather than fat. Studies of GLP-1 medications suggest 25–40% of total weight lost can be lean mass when patients don't actively protect it.

Losing muscle lowers your resting metabolic rate, weakens long-term weight maintenance, and — especially for adults over 40 — accelerates the strength decline that aging already causes. As next-generation medications get more powerful, this issue gets more important, not less.

That's why every weight loss program at AmpUp Wellness is built around body-composition data, not scale weight. Monthly InBody scans break your progress into fat mass, skeletal muscle mass, and visceral fat — so if muscle starts slipping, we catch it and adjust protein targets, training, or dosing before it becomes a problem. Patients who preserve muscle while losing 15–20% of body weight end up leaner, stronger, and far more likely to keep the weight off.

Will Retatrutide Replace Semaglutide and Tirzepatide?

Probably not entirely. Even after approval, several factors will keep the current medications relevant: insurance coverage and cost typically lag for new drugs by years; some patients respond well to gentler single- or dual-agonist mechanisms with fewer side effects; and dose availability and supply shortages have affected every medication in this class at launch.

The realistic future is a menu of incretin options matched to each patient's metabolism, tolerance, and budget — which is exactly why medically supervised programs matter more, not less, as the options multiply. Choosing and titrating the right medication is a clinical decision, not a trend to follow.

What to Expect From a Supervised Program at AmpUp Wellness

Your first visit is a one-on-one consultation at our private clinic on Linton Boulevard in Delray Beach. We review your weight history, health background, current medications, and goals, then establish a baseline with lab work and an InBody composition scan.

If a GLP-1 protocol is appropriate, dosing starts low and titrates gradually — this is how nausea and GI side effects are minimized, and it's another place where supervision beats going it alone. From there, the rhythm is monthly in-person follow-ups: reviewing your InBody data, adjusting nutrition and dose, and troubleshooting plateaus before they stall your progress.

Most patients see steady loss begin within the first month, with results compounding over three to six months. And because the program tracks body composition rather than just weight, you'll know your losses are coming from fat — not muscle.

The Bottom Line for Delray Beach Patients

Retatrutide is genuinely exciting — a triple-agonist medication showing the strongest weight loss results ever recorded in trials. But it is not available yet, and anything sold as "retatrutide" today is an unregulated research chemical, not medicine.

If you're ready to make progress now, the proven path is a supervised program with the medications that are approved and available. Book a consultation with David Patterson, APRN at AmpUp Wellness — we'll review your labs, discuss whether a GLP-1 protocol fits your health picture, and build a plan you can start this month, not in 2026.

Frequently Asked Questions About Retatrutide

What is retatrutide and how is it different from semaglutide?

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors, while semaglutide activates GLP-1 only. In trials, retatrutide produced roughly 24% average weight loss versus about 15% for semaglutide, though the two have not been compared head-to-head.

Is retatrutide available in Delray Beach?

Not yet. Retatrutide is in Phase 3 clinical trials and is not FDA-approved, so no legitimate provider in Delray Beach or anywhere in the U.S. can prescribe it. Products sold online as "reta peptide" are unregulated research chemicals and should be avoided.

When will retatrutide be FDA-approved?

Phase 3 trial results are expected through 2026, with potential approval following if the data supports it. Timelines can shift, so patients interested in next-generation options should establish care with a supervising provider now.

What should I take while waiting for retatrutide?

That's a conversation for a qualified provider — but currently approved GLP-1 medications like semaglutide and tirzepatide already produce 15–20% average weight loss under proper supervision. A consultation at AmpUp Wellness in Delray Beach can determine which option fits your health profile.

Is retatrutide safe?

Safety is still being evaluated in Phase 3 trials. Phase 2 data showed side effects similar to other incretin medications — primarily nausea and other GI symptoms — plus a modest heart rate increase attributed to the glucagon mechanism. Full safety conclusions must wait for Phase 3 results and FDA review.

‍